A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer

BACKGROUND: Anlotinib is a novel oral small-molecule tyrosine kinase inhibitor (TKI), which can inhibit angiogenesis. The purpose of this study was to evaluate the efficacy and safety of anlotinib combined with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia-Yi, Xie, Xiao-Feng, Chen, Xue-Lian, Zhang, Qiu-Yi, Chen, Li-Ping, Bai, Xue, Lan, Xiao-Feng, Song, Lin, Guo, Jin-Feng, Du, Cai-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130368/
https://www.ncbi.nlm.nih.gov/pubmed/37124484
http://dx.doi.org/10.3389/fonc.2023.1122294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130368/
https://www.ncbi.nlm.nih.gov/pubmed/37124484
http://dx.doi.org/10.3389/fonc.2023.1122294

Ejemplares similares